Abstract
To determine whether recombinant erythropoietin (r-HuEpo) administered to very low birth weight infants could increase hemoglobin F synthesis, or delay its developmentally programmed decline, we determined serially the synthesis of hemoglobins A and F in 15 preterm infants receiving either a placebo or r-HuEpo. There was no difference between the two groups in the proportion of hemoglobin F being synthesized in relation to postconceptional age.
Publication types
-
Clinical Trial
-
Comparative Study
-
Multicenter Study
-
Randomized Controlled Trial
-
Research Support, Non-U.S. Gov't
-
Research Support, U.S. Gov't, P.H.S.
MeSH terms
-
Analysis of Variance
-
Double-Blind Method
-
Erythropoietin / administration & dosage
-
Erythropoietin / pharmacology*
-
Fetal Hemoglobin / analysis
-
Fetal Hemoglobin / biosynthesis
-
Fetal Hemoglobin / drug effects*
-
Hemoglobin A / analysis
-
Hemoglobin A / biosynthesis
-
Hemoglobin A / drug effects*
-
Humans
-
Infant, Low Birth Weight
-
Infant, Newborn
-
Infant, Premature / blood*
-
Recombinant Proteins / administration & dosage
-
Recombinant Proteins / pharmacology
-
Reticulocytes / drug effects
-
Reticulocytes / metabolism
-
Time Factors
Substances
-
Recombinant Proteins
-
Erythropoietin
-
Hemoglobin A
-
Fetal Hemoglobin